Zinc supplementation for pediatric pneumonia

Therapeutic role of zinc for pneumonia

The use of zinc as adjunctive therapy for pneumonia was evaluated in several countries. Results from a randomized, double-blind, placebo-controlled trial of zinc supplementation (25 mg per day) with antibiotics for radiology-confirmed acute pneumonia in 94 hospitalized children aged 6 to 36 months in Tanzania showed no significant reduction in the duration of hospitalization (incidence rate ratio [IRR] = 0.69; 95% CI 0.45 to 1.06; P = .09) or in the proportion of children hospitalized for less than 3 days (risk ratio [RR] = 0.85; 95% CI 0.57 to 1.25; P = .40) and less than 5 days (RR = 1.01; 95% CI 0.83 to 1.23; P = .92) when compared with placebo.¹³ Moreover, no significant differences were observed between groups in the duration of fever, tachypnea, nasal flaring, chest indrawing, or changes of antibiotics. Vomiting within 15 minutes of treatment was also not significantly different between groups. The mean change in plasma zinc concentration per 12 hours of hospitalization was not significantly different between zinc-supplementation and placebo groups.

Among 96 Chinese children aged 1 to 12 months hospitalized owing to severe pneumonia, those with low serum zinc levels were assigned to treatment or control groups.¹⁴ After treatment, serum zinc levels increased in the treatment group and returned to normal levels on day 12 (SD = 2); however, no statistical differences were detected in the mean (SD) length of hospital stay (9.0 [6.0] vs 7.0 [4.0]; P = .12) or duration of mechanical ventilation (6.0 [5.0] vs 3.5 [3.0]; P = 0.13) between groups. Similarly, in a 2011 systematic review of 4 trials with 3200 children aged 2 to 35 months in Bangladesh, Nepal, and India, adjunctive zinc supplementation failed to show a statistically significant effect on clinical recovery from both severe and nonsevere pneumonia (fixed effect RR = 1.02; 95% CI 0.93 to 1.11).¹⁵ There were no significant differences in resolution of tachypnea, chest indrawing, or duration of hospital stay for severe pneumonia between zinc and placebo groups. The role of zinc supplementation as an adjunct to antibiotics for severe pneumonia was further examined in a 2016 meta-analysis with 9 randomized controlled studies of 3000 children younger than 5 years of age.¹⁶ Zinc supplementation did not significantly reduce the time to recovery (hazard ratio [HR] = 1.04; 95% CI 0.90 to 1.19; P = .58), hospital length of stay (HR = 1.04; 95% CI 0.83 to 1.33; P = .74), treatment failure (RR = 0.95; 95% CI 0.79 to 1.14; P = .58), or changes of antibiotics (RR = 1.07; 95% CI 0.79 to 1.45; P = .67) when compared with placebo. No significant differences between groups were observed in death rate, adverse events (vomiting and deterioration), or recovery times for severe pneumonia indicators (tachypnea, hypoxemia, chest indrawing, and fever).

A meta-analysis of 7 randomized controlled trials with 1066 children from developing countries, hospitalized for severe acute lower respiratory tract infection (ALTI, defined as respiratory rate more than 50 breaths per minute with crepitation on auscultation and chest indrawing, with or without hazardous signs), compared the therapeutic role of zinc with placebo.¹⁷ Time of resolution of severe illness (standardized mean difference of −0.15; 95% CI −0.5 to 0.2; P = .4) and duration of hospitalization (standardized mean difference of −0.29; 95% CI −0.68 to −0.09; P = .13) were not statistically different between groups. Moreover, no significant differences between groups were noted in time to resolution of all parameters (hypoxia, chest indrawing, and tachypnea), change of antibiotics, or treatment failure rates. Adverse events other than vomiting (odds ratio of 0.25; 95% CI 0.20 to 0.30) were not significantly different.

The combined current evidence suggests there is no role for the prescription of zinc as an adjunctive therapy for pediatric pneumonia.

Prophylactic role of zinc supplementation

Several studies have also been exploring the effect of zinc supplementation on prevention of pediatric pneumonia. A meta-analysis published in 2011 included 8 randomized controlled trials in children younger than 5 years of age from developing countries and reported that zinc supplementation alone (10 to 20 mg), for more than 3 months, was associated with a significant reduction in the rate of pneumonia by 19%, with an RR of 0.81 (95% CI 0.73 to 0.90) when compared with the control group (placebo, vitamins, other minerals).¹⁸ Mortality was not statistically different (RR = 0.85; 95% CI 0.65 to 1.11). Similar results were reported in a recent meta-analysis of 6 randomized controlled studies involving 5200 children 2 to 59 months of age in Bangladesh, India, Peru, and South Africa.¹⁹ Zinc supplementation for at least 3 months was associated with a 13% reduction in the incidence (fixed-effect RR = 0.87; 95% CI 0.81 to 0.94) and a 41% reduction in the prevalence (random-effects RR = 0.59; 95% CI 0.35 to 0.99) of pneumonia. However, a randomized controlled trial from Nepal reported conflicting results.²⁰ Zinc supplementation (10 to 20 mg per day) or placebo was given for 14 days to 2600 children aged 2 to 35 months with community-acquired pneumonia. Despite higher serum zinc levels in the treatment group, the median number of days until the first episode of pneumonia 6 months after initial supplementation was not significantly different between zinc and placebo groups, with HRs of 1.02 (95% CI 0.92 to 1.14) and 1.11 (95% CI 0.72 to 1.73) for non-severe pneumonia and severe pneumonia, respectively. These findings suggests that short-course zinc supplementation during an infection does not prevent pneumonia during the following 6 months.

A 2010 meta-analysis with 10 randomized controlled trials included results from 50 000 children younger than 5 years of age with ALTI who received either zinc (daily or weekly with a total dose of at least 70 mg per week) or placebo for more than 3 months. Zinc significantly reduced the incidence of ALTI if it was diagnosed by a health care provider based on rapid respiratory rate and at least 1 other sign (chest wall indrawing, nasal flaring, fever, cyanosis, lethargy, or convulsion) with or without abnormal lung sounds.²¹ The IRR of the zinc group compared with the placebo group was 0.65 (95% CI 0.52 to 0.82), indicating that zinc supplementation reduced the incidence of ALTI by 35% (95% CI 18% to 48%). Nevertheless, zinc did not significantly reduce the incidence of ALTI if it was reported by caregivers (IRR = 1.01; 95% CI 0.91 to 1.12) or diagnosed by health care providers based only on rapid respiratory rate (IRR = 0.96; 95% CI 0.86 to 1.08). Similarly, in a randomized controlled trial in India, the incidence of ALTI (defined as cough with difficult or rapid breathing or chest indrawing, reported by the caregiver) in 272 children 6 to 11 months of age who received oral zinc supplementation (20 mg in 5 mL of syrup) for 2 weeks was lower by 62% (95% CI 0.26 to 0.36) compared with placebo.²²

In summary, zinc supplementation treatment for longer than 3 months in children younger than 5 years of age was effective in preventing pneumonia. Evidence related to supplementation for less than 3 months’ duration is not as strong.